Connor, Clark & Lunn Investment Management Ltd.

Position in KROS — Keros Therapeutics, Inc.

CIK 1596800 VANCOUVER, A1

Position in KROS

as of Jun 30, 2026 · filed Aug 13, 2026 Compact

Position Value

$1,368,369

-$1,478,670 QoQ

Shares Held

127,885

-50.4% QoQ

Ownership

0.645%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

#33

of 131 holders

Holding Since

Sep 2022

8 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

Connor, Clark & Lunn Investment Management Ltd. holds $650,455,382 across 105 Biotechnology names. KROS ranks #58 (0.2% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	135,236	$67,175,777
2	IONS	Ionis Pharmaceuticals Inc	684,236	$54,253,072
3	ARWR	Arrowhead Pharmaceuticals, Inc.	625,569	$50,990,129
4	MIRM	Mirum Pharmaceuticals, Inc.	420,063	$49,176,775
5	REGN	Regeneron Pharmaceuticals, Inc.	42,465	$26,478,625
6	AXSM	Axsome Therapeutics, Inc.	97,698	$23,913,539
7	INSM	INSMED Inc	212,676	$22,675,515
8	VKTX	Viking Therapeutics, Inc.	530,607	$20,698,979

8 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$1,368,369	127,885	-50.4%	Shares	Sole	2026-08-13
2026-03-31	$2,847,039	257,884	-19.7%	Shares	Sole	2026-05-11
2025-12-31	$6,542,604	321,346	-4.1%	Shares	Sole	2026-02-10
2025-09-30	$5,302,136	335,154	+26.1%	Shares	Sole	2025-11-13
2025-06-30	$3,547,188	265,707	+107.4%	Shares	Sole	2025-08-07
2025-03-31	$1,305,369	128,103	+339.5%	Shares	Sole	2025-05-12
2024-12-31	$461,381	29,146	+203.0%	Shares	Sole	2025-02-10
2022-09-30	$361,904	9,620	—	Shares	Sole	2022-11-10
No filing history on record for this holder in this stock.